BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

857 related articles for article (PubMed ID: 9225643)

  • 21. Intrauterine devices. The optimal long-term contraceptive method?
    Fortney JA; Feldblum PJ; Raymond EG
    J Reprod Med; 1999 Mar; 44(3):269-74. PubMed ID: 10202746
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of copper intrauterine device with levonorgestrel-bearing intrauterine system for post-abortion contraception.
    Bilgehan F; Dilbaz B; Karadag B; Deveci CD
    J Obstet Gynaecol Res; 2015 Sep; 41(9):1426-32. PubMed ID: 26180028
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of oligoamenorrhea at 1-year follow-up in premenopausal women using a levonorgestrel-releasing intrauterine system.
    de Jonge ET; Yigit R; Molenberghs G; Straetmans D; Ombelet W
    Contraception; 2007 Aug; 76(2):91-5. PubMed ID: 17656176
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of the levonorgestrel-releasing intrauterine system in women with hemostatic disorders.
    Lukes AS; Reardon B; Arepally G
    Fertil Steril; 2008 Sep; 90(3):673-7. PubMed ID: 18001734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Uptake of the levonorgestrel intrauterine system among recent postpartum women in Kenya: factors associated with decision-making.
    Hubacher D; Masaba R; Manduku CK; Veena V
    Contraception; 2013 Jul; 88(1):97-102. PubMed ID: 23566383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subject and clinician experience with the levonorgestrel-releasing intrauterine system.
    Jensen JT; Nelson AL; Costales AC
    Contraception; 2008 Jan; 77(1):22-9. PubMed ID: 18082662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Levonorgestrel-releasing intrauterine system: why do some women dislike it?
    Daud S; Ewies AA
    Gynecol Endocrinol; 2008 Dec; 24(12):686-90. PubMed ID: 19172537
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intrauterine devices and intrauterine systems.
    ESHRE Capri Workshop Group
    Hum Reprod Update; 2008; 14(3):197-208. PubMed ID: 18400840
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of vascular endothelial growth factors and their receptors in human endometrium from women experiencing abnormal bleeding patterns after prolonged use of a levonorgestrel-releasing intrauterine system.
    Möller B; Rönnerdag M; Wang G; Odlind V; Olovsson M
    Hum Reprod; 2005 May; 20(5):1410-7. PubMed ID: 15760960
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of two cohorts of women who expulsed either a copper-intrauterine device or a levonorgestrel-releasing intrauterine system.
    Simonatto P; Bahamondes MV; Fernandes A; Silveira C; Bahamondes L
    J Obstet Gynaecol Res; 2016 May; 42(5):554-9. PubMed ID: 26817571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An evaluation of the levonorgestrel-releasing IUD: its advantages and disadvantages when compared to the copper-releasing IUDs.
    Chi IC
    Contraception; 1991 Dec; 44(6):573-88. PubMed ID: 1773615
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hormonal intrauterine devices.
    Rybo G; Andersson K; Odlind V
    Ann Med; 1993 Apr; 25(2):143-7. PubMed ID: 8489751
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ease of insertion, contraceptive efficacy and safety of new T-shaped levonorgestrel-releasing intrauterine systems.
    Wildemeersch D; Janssens D; Vrijens M; Weyers S
    Contraception; 2005 Jun; 71(6):465-9. PubMed ID: 15914138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Levonorgestrel IUD].
    Skajaa K; Forman A
    Ugeskr Laeger; 1994 Nov; 156(46):6884-7. PubMed ID: 7839510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The levonorgestrel intrauterine system in nulliparous women.
    Prager S; Darney PD
    Contraception; 2007 Jun; 75(6 Suppl):S12-5. PubMed ID: 17531602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detailed analysis of menstrual bleeding patterns after postmenstrual and postabortal insertion of a copper IUD or a levonorgestrel-releasing intrauterine system.
    Suvisaari J; Lähteenmäki P
    Contraception; 1996 Oct; 54(4):201-8. PubMed ID: 8922872
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of menstrual blood loss in Brazilian users of the frameless copper-releasing IUD with copper surface area of 330 mm2 and the frameless levonorgestrel-releasing intrauterine system.
    Andrade AT; Souza JP; Andrade GN; Rowe PJ; Wildemeersch D
    Contraception; 2004 Aug; 70(2):173-7. PubMed ID: 15288225
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sixty thousand woman-years of experience on the levonorgestrel intrauterine system: an epidemiological survey in Finland.
    Backman T; Huhtala S; Tuominen J; Luoto R; Erkkola R; Blom T; Rauramo I; Koskenvuo M
    Eur J Contracept Reprod Health Care; 2001 Jan; 6 Suppl 1():23-6. PubMed ID: 11336430
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis.
    Sheng J; Zhang WY; Zhang JP; Lu D
    Contraception; 2009 Mar; 79(3):189-93. PubMed ID: 19185671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety of levonorgestrel 52 mg intrauterine system compared to copper intrauterine device: a population-based cohort study.
    Bosco-Lévy P; Gouverneur A; Langlade C; Miremont G; Pariente A
    Contraception; 2019 Jun; 99(6):345-349. PubMed ID: 30871933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.